Практика Shadowing: Biotech Story Time With Tal Zaks, M.D. (Part 1) - Изучайте разговорный английский по видео

Выберите режим практики

Каждый режим открывает полноэкранную комнату практики.

724 предложений

Если предложения слишком короткие или длинные, нажмите Edit, чтобы их изменить.

you know arrows i was uh i was thinking before i came into the studio today

that i should have i was thinking i should have made

a large bag of popcorn for today's episode do you know

why why do you remember the last time we talked with tall tall zacks uh it's been a while

but i remember being wrapped wrapped entertained uh the stories were

uh just titillating right like i was on the edge of my seat uh sometimes in disbelief

and i thought this is a popcorn worthy episode alas i

did not bring any popcorn to my chagrin i'm sorry next

time bad planning a lot of people know him as the

guy who was chief medical officer at moderna before during

and after the company became a household name thanks to its mRNA -based answer to COVID.

But even without that gold star next to his name, Dr. Tal Zaks has built a fascinating career as a physician scientist,

an investor, a board member, and a biotech builder.

Today, he's CEO and chair of the board of directors at Exilio Therapeutics, a non -executive director at five companies, I think, including Teva Pharmaceuticals,

a private equity partner at Orbimed, and probably holds a few more titles

that i'm missing storyteller he's a he's a not

that we're setting the bar too high for right now

but he is a prolific storyteller dr seuss over here i'm matt pillar

and i'm anna rose welch

and on today's episode of the business of biotech it's story time with fall

so stay tuned

because the stories tall tells are not tall tells although i

guess they would be tall tells just not in the way

you think i meant it that's a new level you didn't see

that coming and

that really hit me over the head like a shovel his

stories are packed with biotech business building insights gained over a

career spent uh spanning leadership roles at gsk sanofi teva moderna orbamed

and now exilio therapeutics

and probably like i said a whole lot more tall welcome

to the show it's a real pleasure to be here we are absolutely thrilled to have you

and as i said i i'm I'm sorry if we set the bar too high, but the last time we chatted, Hannah Rose and I came away thinking like this guy has got

so many great anecdotes that not only like not only great stories, but like a lot of meat in them.

Right.

A lot of meat for biotech builders.

So we're really looking forward to the conversation today.

We have a ton to get through.

I don't know if we'll do it all in one one episode.

We might have to revisit with a part two.

But before we get into the Exilio story, I want to get to know you a little bit and intro you to the audience.

And so and I'm going to go way back.

We're going to rewind the clock quite a ways.

You immigrated to the U .S from Israel to do your postdoc at the National Cancer Institute

and presumably at the time practice medicine.

I mean, you're you know, you you practice medicine back then.

Well, when you when you made that move, was it was that your sole intention career wise to come over here and practice?

uh to be fair back in the day i just had

an opportunity to come to the mecca of scientific research now

i trained in the early days as a physician scientist an

md phd it wasn't really a track i sort of built it

because i got interested in an area of medicine uh that's called tumor immunology back then it wasn't the thing

that it has become since but i was super curious

and i had a wonderful opportunity to come to the lab of dr steve rosenberg at the national cancer institute

and you know as an immigrant coming from across to the mecca of the nih

you don't really think what's going to happen next you just say boy i'm at a place

that has really redefined our understanding of immuno -oncology benefits for patients with cancer

and the sky's the limit

and i have to tell you i am to this day a very proud immigrant to this country and really

if anything have been fortunate to take advantage of an ecosystem

where truly the sky's the limit in terms of what we can achieve for uh for patients for ourselves for mankind

so i in all honestly i knew i was a physician i had some interest in science

and i just wanted to explore it yeah you just went and

that ecosystem has opened up a lot of doors you know

on in the periphery in front of you maybe in some cases behind you

and you've taken you've seemingly taken advantage of every door that's

presented itself well to be fair uh i have to say

the first three years were actually marked by a lot of failure uh

and in fact after three years there i you know, try to get a cancer vaccine to work.

I actually proved why it didn't work.

I tried to understand immuno -oncology.

We had a theory as to what could be what what are today called checkpoints.

We actually debunked it and it wasn't that.

And after kind of three years, I said, oh, you know.

I better go back and finish my clinical training.

Yeah.

And and it taught me the value of scientific depth.

But I can tell you years later, when I came upon a saying by the late Nelson Mandela, it's become my favorite quote of all time.

And he said, in life, I've either succeeded or I've learned.

To be fair, in those early days, I had a lot of learnings.

Still do to this day.

Yeah, it's a it's I mean, it's a common refrain, but it's it's it's like there's a dichotomy.

It's like there's a it's a common refrain, but it's all too often forgotten in this in this industry.

Right well and i think you know we tend to just package it as well

that was a failure instead of a learning right it's really just a terminology change

but you know reframing that reframing it after you i do think i do think

that when things don't go as expected that's actually when you grow

and when you learn the most in fact in a roundabout way um

and we'll come back to this later one of the fascinating

things for me to reflect on covid was here's something

that succeeded beyond my wildest expectations so you know what did i learn from

that because there are learnings from that success

but it's actually uh you know maybe counterintuitively it's easier to

learn from failures than it is it is from successes yeah uh sticking back in

that in that time frame after you completed your residency at temple

and your fellowship at penn you joined gsk to work in clinical development translational medicine

so tell us tell us why you made that transition to industry

i have to say

that was a completely non -obvious move to me at the

time um i had spent many years in training in academia

100

you know an internship another internship a residency a postdoc a fellowship

101

and uh uh in in as i was finishing my fellowship

102

i i actually uh won an asco young investigator award this

103

thing handed out to fellows you've got a little bit of research budget

104

and and and i came home really proud my son who was 12 looks up at me

105

and says dad what's what's all the commotion about i was clearly excited

106

and i look at him

107

and said well you know i just i just won this young uh investigator award

108

and the kid looks up at me

109

and says dad what do you mean young investigator award like how old are you

110

and i look at the kid

111

and he had a point uh you know i was in my 38 39

112

and and he's 12 and heading up to college in a few years

113

and and here i am having fun training learning seeing patients

114

but it really kind of brought it home

115

that okay maybe it's time to actually go do something in the world and

116

while I trained myself thinking I was going to be an

117

academic physician I started my life actually as a pediatric intensive care unit nurse

118

and I worked as a nurse on that side of the patient's bed

119

if you will as I was training to be physician

120

and i always appreciated teamwork

121

and you know the academic uh world is driven by the axiom

122

that there can only be one first author a few years before

123

that i interviewed at a very prestigious institution and for fellowship

124

and they said great yeah we'll have you as a fellow

125

and with a little bit of chutzpah i asked them well you know

126

if i come here as a fellow how quickly can i be faculty

127

and they said oh okay let's let's think about

128

that they took it up the flagpole

129

and down came the answer it said look we we looked

130

at your uh resume yeah you did a postdoc at the nih you had some papers great

131

but you actually had more second authorships than first authorship

132

so we're not really sure about you

133

and i have to tell you i like i really took

134

that to heart because i was actually more proud of the second authorships because

135

when you're a second authorship it means you got to be

136

part of something somebody else did the work you got to play a role in enjoying it leading

137

and thinking through it uh while you were doing other stuff as well uh

138

and so when the time came to sort of make the career move the the notion

139

that uh i could actually go do it in a more team -based environment where really the purpose was getting better drugs.

140

I just found that appealing.

141

And, you know, if you take a medicine and you open it up, you know, whether it's tabs or a vial,

142

you'll see there's a piece of paper rolled up in that that most people throw away.

143

Well, if you open up that paper, it's actually the label.

144

It's what the FDA says you should use it.

145

And if you look at where, you know, who signed off on that label, where do these drugs come from?

146

Well, they don't come from the university and they don't come from the National Institutes of Health.

147

They actually come from drug companies.

148

And so if you, as your mission in life, want to actually do better, especially in oncology with the state of affair of drugs,

149

while we have very good drugs, we should and could do better and you want to be part of that doing better, then you go to where the action is.

150

You go to where these medicines are made to have an impact.

151

And that's sort of what propelled me to, despite having trained for so long, to be an academic physician, to actually shift gears and try it out in industry.

152

Speaking of being in the place that makes the medicines, you continue to play your hand at a place that makes a lot of medicines in Teva.

153

You've been there since 2021 as a board member.

154

It's one of the world's largest generics companies.

155

Tell us about that experience and how it's informed your take on the market.

156

I have to tell you, I'm super proud of that.

157

And I'm proud at a very deep level,

158

because what Teva does is a reflection of the breadth of contribution to our industry that's often lost

159

when we think of purely innovative companies.

160

The innovation at the heart of the ecosystem is protected by intellectual property.

161

And that is the engine that's allowed us to be

162

so productive in the U .S in the last 50 years as the leaders of the world of therapeutic benefit.

163

But the beauty is that that

164

that contract with society actually plays out in the long run once the intellectual property expires and you now have generic medicines.

165

And, you know, the stem pill I take every morning

166

and the fact that my late father managed to live for 40 years with chronic heart disease and, you know, taking five, six, seven different meds.

167

Those were all generics or most of them were.

168

And by now, all of them are.

169

Right.

170

Right.

171

And so the benefit of the previous era is now available to society at a fraction of the cost.

172

Thanks to that.

173

And in the discussion that we have about, you know, cost of drugs and intellectual property and all the other stuff,

174

we often forget that there's a very long tail of benefit

175

that we just keep raising the bar

176

and then the price goes down years later for everybody to enjoy

177

and that's worldwide and

178

so i take tremendous pride in teva's contribution both on the

179

innovative side we are an innovative company we we do develop innovative medicines

180

but also on the generic underpinning of that

181

that provides drugs for hundreds of millions of people every day freeze up right it frees up cost right

182

and money to be able to cover the innovative stuff right the the breaking, the breaking new drugs on the market that, that aren't as cheap as generics, right.

183

Or as, as biosimilars.

184

So it's really, it pays into that innovation in its own way.

185

Yeah.

186

It's good illustration of, uh, Dr. Zacks is, uh, I guess, um, the breadth of his portfolio, right?

187

Like the things, I mean, we're going to talk about Axelio here pretty, pretty soon, uh, doing some pretty novel and exciting things.

188

And he did obviously some pretty novel and exciting things uh beginning in 2015

189

when he took on the stint as cmo at moderna

190

so we could spend like i don't want to do this

191

i don't want to do this i want to get i want to give this its fair share

192

but we could spend a couple episodes talking about stories from

193

yes those moderna days of moderna age you know like not

194

to not to put too fine a point on it but you joined moderna in 2015

195

like just let that sink in for a minute what tell us about that like you you start like was this

196

was this a right place right time kind of situation was

197

it like you you saw something coming like what's what's the

198

story there how are you reading the tea leaves what's going on oh i wish i could be

199

that smart uh you know uh i i was listening to

200

a podcast a few uh weeks ago general petreus uh made

201

a comment he referenced uh the late uh long late roman philosopher Seneca who said that luck is when preparation meets opportunity.

202

So in a way, I was prepared.

203

I had spent a significant chunk of my life by then in oncology drug development.

204

As you mentioned, I started GSK, ended up running Santa Fe's global oncology team.

205

And at that point, I had sort of the opportunity to kind of look around at the biotech system and figure out,

206

well, what's new that's coming and what are some interesting ways to fill our pipeline

207

and up until that point i was a medical oncologist through

208

and through i cared about better medicines for cancer patients i

209

didn't care about where they were coming from the proof point

210

i actually spent a couple years at cephalon cephalon had developed

211

two of the oldest poisons known to man as a very effective cancer chemotherapies.

212

One is arsenic trioxide, which cures a subset of leukemia.

213

So Fine by me, right?

214

The clinical benefit is what speaks to me.

215

But as you're a scientist and you get sort of curious about where's innovation coming from,

216

I had the opportunity to look within the Boston ecosystem at a whole bunch of stuff.

217

And I came upon Moderna and the idea of mRNA.

218

And it made me stop and sort of think differently about translating science into medicine

219

so by then i sort of realized that i was my happy place

220

if you will is is between the science

221

and the medicine not pure science for the sake of science not just pure medical practice even though i did

222

that a number of years as a volunteer at the philadelphia va

223

but it's actually that in between and moderna was had an emerging interesting idea

224

and platform that was very orthogonal to my thinking.

225

It was not, hey, we have a cancer patient and cancer here as a need.

226

Can you make a medicine?

227

It was we have this innovative idea of a new platform.

228

And if we can translate it into medicine, what would those medicines be?

229

And that's a very different way of asking the question.

230

Now, in full transparency in 2015, all the data we had were just an animal model in mice uh

231

and most people thought this thing was never going to work uh i have been fortunate in life that in

232

that uh my wife who's the smart one in the equation

233

actually has a phd in biochemistry you know she looks at me

234

and says well you know it's all mrna it's high risk

235

but hey if this speaks to you go for it

236

and i was in a place in life where uh it was time to take risk

237

you know and the way to think about it um i had a big birthday

238

that year and one of the things that happens

239

when you reach a certain age is

240

that you stop looking at the next career thing you're going

241

to do you start looking at time in reverse you said okay

242

and the time

243

that left to me in this world what do i want to get done what do i want to accomplish

244

and and then you realize you'd rather

245

fail or learn trying to address a big question than just do something small and incremental

246

uh this was a big question this was a question

247

that most people thought was not going to work uh i

248

mean i can show you nature papers back in the day uh referencing moderna

249

and theranos in the same sentence for crying out loud um

250

and and it was a very different way to kind of challenge yourself to go make medicine

251

so i i signed on because i thought that if this would work

252

we should be able to go from an idea on a

253

whiteboard to a medicine being studied in man at a fraction of the time

254

and the cost of what traditional drug development takes.

255

And it had such potential in terms of a platform that could lend itself to once you do the first one,

256

the other ones should actually work that repeatability that is unheard of in traditional pharma.

257

And in fact, we'd actually proven it.

258

One of the things the public is not aware of is that, you know, the COVID vaccine was not Moderna's first vaccine.

259

It was actually the ninth virus against which we tried to raise neutralizing antibodies in humans.

260

And our success rate for the prior eight had been eight out of eight.

261

So COVID for us inside was was not a surprise, actually, that it worked.

262

There were a lot of other things surprising about it.

263

But we knew this platform could actually get there.

264

In fact, for years, we have been working with an urgency to get there in time.

265

So I really like this point.

266

You know, when you joined Moderna, I think the instinct there was to really be part of a foundation, right?

267

You wanted to build the foundation for mRNA medicines.

268

And instead of making sort of incremental advancements, really tried to develop this proof point for mRNA as an actual therapeutic, as a vaccine candidate it

269

but i'm really i'm curious to to learn more about you

270

know your priorities as a cmo stepping into a company at this time

271

when mrna was again as you said compared to theranos right

272

like it wasn't a household name a lot of people were hesitant to believe

273

that it would work it was high risk you know what were your priorities as a cmo

274

when you stepped into this into this company and

275

and in these early days what did that what did

276

that look like

277

and entail i think uh a lot of moderna's success stems from two factors the first is the courage that those

278

that came there before me um stefan boncel steven hoog uh to ask the question don't you know suspend disbelief

279

if it works what can you do of it?

280

And then the very thoughtful risk mitigation approach to try

281

and take several shots on goal in different dimensions to try to work yourself across different things that could work, but you don't know that they could.

282

In those days, they spanned infectious disease these vaccines, they spanned.

283

uh oncology efforts they spanned rare disease uh one of the things

284

that i personally started uh shortly after joining was the personalized cancer vaccine uh

285

and you know we can come back to that uh you know

286

if you want a cliffhanger into this episode we can talk about cancer vaccines

287

because it's a fascinating story in fact it's much more fascinating to me scientifically than than even covid

288

but when i joined uh and and this is where your popcorn will will find a place

289

when i joined in march of 2015 uh stefan von selva

290

ceo asked me to give uh an all -employee town hall uh three months into my tenure

291

so in june of 2015

292

and he wanted me to explain to the employees there were

293

about 300 people at modern at the time why was it

294

that a unicorn on paper company in boston uh

295

so secretive is actually the first clinical trial is going to

296

be a vaccine against the pandemic flu threat out of china

297

that was our first phase one we started at the end of 2015. and

298

so what we did back in those days is we used

299

to rent the the auditorium next door uh it was actually

300

a movie theater the kenthal square theater um we used to

301

rent it out for random thursday afternoon we'd give all the employees free popcorn they'd sit

302

when the executives would get on stage and

303

and you know tell the story of what the company was up to in the last couple months

304

and so it's my turn june of 2015

305

and i told us to fund great we're in a movie

306

theater i'm going to take some license with my presentation i'm

307

not going to use your usual slide template i'm going to make believe we're in a movie and

308

so i get up everybody's with popcorn i'm the new cmo

309

said guys pretend this is a movie the the theater goes dark

310

and on the screen comes a slide

311

and the title of the movie is how moderna will save

312

the world june of 2015 the next slide is a pg -13 green rated thing right to get everybody

313

and then the rest of the presentation

314

started with the spanish flu in 1918 goes through the fact

315

that still back then in 2015 we don't have a good

316

vaccine response we don't have good antivirals all we have is

317

these masks these picture of people walking around in masks

318

and i flashed those pictures up in june of 2015

319

and basically the gist of the talk was our platform it's

320

clear the low -hanging fruit is going to be vaccines for a whole host of technical reasons

321

and we owe it to ourselves to the company to society to make sure

322

that we're advancing these vaccines both those that are of perceived commercial value

323

and those that could be of public benefit

324

and in fact that's what we proceeded to do we had advanced a few candidates

325

that have commercial background i mean cmv right now uh is already in in phase three there uh

326

but in parallel we worked on flu we worked on zika in 2017 that's

327

when part of the u .s government got to go and

328

and we built this track record of the ability of this platform to actually execute towards a pandemic need uh

329

and i'll tell you it came full circle In September of 2019,

330

Stefan and I went down for our sort of annual meeting with the NH folks, who was there at the time,

331

and they came to know us through the Zika pandemic in 2017, and we started to collaborate.

332

And by then, we had shown

333

that the mRNA vaccine could actually work to protect an animal model of a cousin of COVID called MERS.

334

uh and i we were telling uh the team there about the most recent data we had

335

and i remember at some point dr fauci kind of stops me

336

and says so are you telling me this is the best vaccine platform i've ever seen uh -huh

337

and you know me being me i basically looked at the same dr fauci yes

338

and let me explain why and and and so the upshot of

339

that meeting was actually that Moderna and the NIH were going to form a collaboration to pick a virus,

340

something nobody ever heard of.

341

We'll just send you the sequence.

342

You guys can start the clock, see how fast you can make a first batch, and we'll run the phase one clinical trial.

343

And in November, the NIH, November of 2019,

344

Dr. Fauci actually published a paper talking about pandemic preparedness of various platforms

345

and mentions mrna there as the leading platform ready to serve in a pandemic whether it's influenza

346

or a related respiratory virus

347

and as we were talking to the nh trying to figure out what would be

348

that test case somebody started coughing into wuhan

349

and the rest is oh my gosh uh you realize how

350

much fodder you're you're providing for conspiracy theorists right now dr

351

zacks i mean really takes time to a whole new level where's my popcorn i know

352

but i'm curious so i i i can tell you just to finish the note

353

because i i have to say uh you know I got to know all sorts of conspiracy theorists back in 2020.

354

One of my, I think, learnings from the whole era was how critical it is

355

that we build public trust and understanding and what it is we do.

356

If if if we do everything we do in translating science into medicine, but the public doesn't trust it, then it will have been for not.

357

And I spent a lot of energy as the chief medical officer back in those days.

358

And I still believe it's part of each and every one of our ethical obligation to be out there,

359

to tell the story, to explain to people where does this stuff come from?

360

This is not black voodoo.

361

This is not some magic mystery.

362

This is people hard at work trying to understand the science and trying to translate that science.

363

And we did we did a couple of things that were I'm really proud of back in that era.

364

The first was in as the phase three trial was going on.

365

I remember being on a on a on a webinar with the National Academy of Sciences of New York State, and they asked me, OK, at the end of it, there was a Q &A.

366

And they said, Dr. Zax, what are you worried about?

367

And and they expected me to say, oh, I don't know if it's going to work this.

368

Then the other said, look, I'm not worried about safety.

369

I'm not worried about efficacy.

370

The one thing that keeps me up at night is that our trial enrolls people of diverse enough

371

representation of the great country of ours so that when the data comes out, people can relate to the veracity of those data and can see themselves in the trial.

372

And I think Moderna went on to really pioneer enrollment of diverse populations in phase three and in all subsequent trials,

373

partnering with both national and regional sort of experts

374

and leaders of the community to make sure that clinical research is both accessible to everybody and representative of everybody.

375

And the other interesting thing was, again, as I was thinking, how do we relay this message to the public?

376

I actually convened a small ethics panel for the executive team at Moderna.

377

You're not going to find this on any website.

378

This was not done for external consumption.

379

This was really to get external advice of people like Art Kaplan

380

and other experts in ethics on how should we be thinking about our protocol.

381

And one of the experts there, a friend of mine, Ann Beal, Ann is a wonderful black pediatrician from New York City.

382

She was the first chief patient safety or chief patient officer at Santa Fe.

383

She's today on the board of GSK.

384

And I brought Ann in and Ann looks at me and says, Tal, I've been in your shoes.

385

The only way you can do this is to be transparent to the point of discomfort

386

and i listened and i said that's going to be the motto of our medical affairs organization

387

and in the ensuing weeks we had a lot of internal

388

conversation i was pushing to have the phase three protocol of the covet vaccine actually published

389

and companies don't usually publish protocols uh on the web certainly not unredacted

390

and certainly not as the trial is still ongoing

391

and we finally prevailed and in september we we we went out uh

392

and we put the entire protocol on the web

393

and i'm very happy to say

394

that all the pharma followed some of them within hours we

395

got one of the most favorable articles ever written on pharma on the new york times in september of 2020

396

but more importantly journalists who used to call me up in those days

397

and say hey you know what are you not telling me

398

how many patients are you going to sea etc suddenly the

399

conversation was tall on page 87 paragraph two of your protocol

400

can you explain to me how the power of the statistics work right

401

so you could actually take now the conversation with the public

402

and i you know i have tremendous respect for to journalists

403

because at the end of the day you're the ones who

404

translate this to do what the public actually gets to listen and and figure out.

405

And so it changed the dialogue that we had with the public on what that protocol was actually trying to do.

406

He says one of the most favorable articles on pharma, the New York Times is, I'm thinking like a favorable article on pharma is a win,

407

and it doesn't have to be one of the most, right?

408

I mean, if it's...

409

Penny one is a win.

410

If it's 52 % favorable, that's a win.

411

No, I really, you know, so I think you kind of answered this, this question that I have.

412

But so, you know, you built this foundation, you weren't concerned necessarily about mRNA being efficacious and safe.

413

The big priority for you as the pandemic started to hit in the in the year after, right, as you released your vaccine was really making sure

414

that you were telling the full story and that everyone who needed to

415

and wanted to see that data could actually access it and be able to able to understand that story, you know.

416

Was that perhaps the biggest part of your leadership at

417

that time as a CMO in an MRNA company once it kind of became a public good, right, a publicly known household name?

418

Or how did you see your priorities sort of shifting as MRNA suddenly became an actual medicine

419

that was commercialized and you had to continue moving forward and being a CMO of this company?

420

Yeah, I think that's true.

421

So if you if I look back at 2020 and now, you know, with the wisdom of insight, it really is there's two parts to that year.

422

And the first part, when we sort of had to muster up

423

and figure out how to get this done

424

and how to do it in a way that would avoid all the obvious pitfalls.

425

And by the way, how to do it while learning to work in a completely novel manner.

426

That was all consuming.

427

I mean, if you would have told me in 2019

428

that I'd be developing a vaccine in 2020 and I'd be doing it with a team of dozens of people,

429

all of whom I had hired through Zoom and never met.

430

And I would be doing it with three government agencies who had to align on protocols and endpoints,

431

none of whom got in the room together with each other, let alone me um

432

and i do it in record time such

433

that we went from an idea on a whiteboard to an

434

authorized vaccine in 11 months i would have thought yeah that's that's that's impossible

435

and yet and yet we did it and

436

so that's where you kind of there's learnings from that success in terms of how we work

437

across uh individuals and what can work with remote working

438

and zoom and what actually takes people to get in the room together to align on things

439

and and i think we as a society are still learning that lesson

440

but it's clearly i think for us the development of the vaccine was probably a unique edge case

441

that everybody else experienced in terms of what can you get done remotely

442

and how to go about building a an effective remote working

443

environment the second half of the year I think once the phase three was sort of rolling on its tracks,

444

and then I had to pay attention to two things.

445

I think one of them is, as you said, being the public face, making sure that I can tell the story, that I can represent Moderna.

446

We had very critical FDA meetings, advisory committee meetings cdc meetings etc the other one

447

that is a story that's not often told actually has to do with safety

448

and what people sort of don't realize is and probably this is

449

this is a good explanation for some of the conspiracy theorists out there

450

The mRNA vaccines are the most intensively studied from a safety perspective, medical intervention in the history of humanity.

451

We have dosed, I don't know, one, two billion people with these medicines.

452

We've done it with the most modern tools for data collection ever available to mankind.

453

We've done it with reporting through all forms of modern communication technology.

454

We've done it using the best tools available today of big data analyses for any kind of signal.

455

And the proof is that when you had very rare adverse events

456

that happen at a rate of 1 to 150 or 1 to 200 ,000 cases, those were picked up within months.

457

And that's what happened to the AstraZeneca vaccine, the J &J vaccine, if you recall back.

458

And even Moderna had this this very low signal of the myocarditis that had been picked up and then validated.

459

So there's I don't think there's anything significant about the safety of these vaccines that we don't know.

460

It just doesn't make any sense given the way we collected.

461

And I can tell you the amount of man hours, hundreds of millions that it actually cost to collect the safety data.

462

That is the iceberg under the water.

463

And to the degree that I was sort of steering the ship in those days, that was the thing that I had to pay careful attention to,

464

to make sure that we are actually collecting the data as required by regulations.

465

And by the way, global regulators around the world would have weekly teleconferences without me, FDA, the Europeans, et cetera, et cetera.

466

And they would be talking about the safety of our vaccines and what it is that they get direct reporting.

467

And when you think about it.

468

just to give you a numbers on it

469

when we started down this path we took a look at the previous vaccines launched

470

and we thought that we would get about three to four times the reporting of adverse events

471

that any other vaccine would happen that's what we geared up to

472

when it actually got rolled out we got about 15 folds i mean i don't remember the exact numbers

473

but it was over tenfold what we had expected

474

because of this heightened sense of vigilance because of the public scrutiny

475

and all rightly so and it was our job to react to

476

that collect the data sift through it and make sure

477

that we report it accurately and so that's a story that's not often told

478

but for me was critical so that i can be out there

479

and and and say yep you know

480

if you want to know what the side effects are you remember

481

that fda label go back and pull it up because if there's anything we saw by law, it's on there.

482

And we're having those conversations with the FDA to tell them about it.

483

Yeah.

484

You know, very few, it occurs to me, the very few, very few CXOs in a similar,

485

will ever find themselves in a similar position where that one moment, moment in time, you know,

486

really throws the afterburners of your career on, right?

487

Like very few people are going to see that and very

488

and fewer still fewer still people are going to survive it

489

come out the other end like you know hey the contributions

490

there being biotech yeah i i stand on it um

491

so you know it goes without saying that that

492

that had to have been a supreme confidence builder even even in your already very successful

493

and advanced career that had to be a supreme confidence builder

494

but and and as i said we could talk about covid for like the next three hours

495

but um i want to i want to kind of shift back to like what, what makes Dr. Talzak's, Talzak's who he is today and,

496

and kind of keeps him moving forward.

497

So taking sort of, sort of that specific experience off the table, what other inflection points during your, you know, CXO, you know,

498

VP, even research experiences with your previous companies have in a similar,

499

but maybe more muted, more muted to the public way influenced, uh, your confidence in, in your,

500

uh, career trajectory, you know, your decisions to go on and be a, be a board guy, be a founder, be a, you know, uh, the, the leader of Exilio, for instance, now.

501

Uh, it's a combination of factors, you know, it starts with the absolute joy.

502

of seeing clinical benefit come at the other end.

503

I'll tell you a story back when I was at Sanofi.

504

We had a drug that was in phase one, just the first phase of clinical research.

505

And it was, it targets something called CD38 for patients with a type of blood cancer called multiple myeloma.

506

And this phase one had been going on for very long because we started at very low doses.

507

We were going very, very slowly, and it wasn't clear that it was going to work, so people weren't excited to enroll.

508

And one day, the team comes back and tells me, you know, you remember that 70 -year -old patient that we had, and he'd just gotten a couple of doses?

509

Well, he decided to go off protocol, and he's no longer participating.

510

I'm like, why?

511

You know, we just lost the data point.

512

This is hard enough as it is.

513

And they say, well, you know, here's what happened.

514

We gave him two doses

515

or three doses of the drug he went into a complete

516

response he's 70 year old he's been feeling like crap for

517

the last decade of his life he finally got the opportunity to go to europe

518

and take the summer off and do that trip he's been dreaming up

519

so he decided he's not coming for his next dose he's going off to europe to live right

520

and then you go okay i guess i guess that's okay

521

that's what we strive for right improve quality of life exactly

522

so uh so so it's those stories that that you sort of

523

that you live for on the you know i i think i've been fortunate to to have mentors and colleagues

524

to be able to talk to and have have sort of steered me right whether it's people like steve Rosenberg,

525

who is still there at the NCI now 50 years as the towering modern giant father of immuno -oncology.

526

I mean, a lot of therapies we see today, the T -cell therapies all started in his lab back in the day.

527

I've been fortunate to have a supportive wife who understands what I do

528

And more than that will actually tell me to my face

529

when I'm talking nonsense and tell me the stuff I don't want to hear.

530

And I've been blessed with having colleagues, you know, one of the.

531

privileges that we have in the world in this ecosystem is

532

that the end game is something tangible

533

that is easy to be passionate about we're not making widgets

534

we're making people feel better live longer we're trying to cure diseases we're trying to prevent horrible illnesses it is easy to get

535

that as a rallying cry what's hard is then to figure

536

out okay with all the unknowns in biology along the way how do you do

537

that now in the i i think this in in this phase of my career

538

one of the things i learned at moderna sort of through

539

doing is the importance of aligning return on investment with uh with kind of innovation and doing good for patients

540

and it sounds trite but it's actually not obvious and it's not trivial to get right the

541

Our ecosystem has been so productive, but you have to understand the drivers of this ecosystem,

542

because if you look at other economic models of trying to translate innovation into health care benefits, they have not worked nearly as well.

543

And so I judge it by the results

544

and I am deeply respectful of the underlying economic ecosystem

545

that rewards innovation and rewards investment in high risk areas with a return on that investment.

546

you know i was um i was kindly invited to a recent uh summit

547

that uh one of the national academy of sciences medicine

548

and engineering had about how to better align uh investing in innovation

549

and therapeutics with unmet need and

550

and one of my points to them was i i'm not ashamed of saying return on investment

551

when we talk about drug pricing uh you know we we we often talk about

552

kind of reimbursement and reimbursement is a term that is fit for

553

when i go out and have a meal

554

and i need somebody to pay for the meal we don't

555

work for reimbursement let's be fair we work for a return

556

on the investment my shareholders my limited partners right now in

557

venture a lot of them are pension funds they give me

558

a pot of money seven years later i need to give them a bigger pot of money back

559

because they got to go pay those pensions that's what propels our system

560

that is commercial investment

561

and for me since i was fortunate to never actually do

562

anything strictly for money uh i became super curious to understand

563

and immerse myself in an ecosystem where

564

that part of the value is actually a very objective

565

and legitimate yardstick um you know sweat equity

566

and capital equity tend to be rewarded differently i've sort of lived now through both

567

and uh when

568

when investors at moderna used to ask me well you know

569

what's the stock price should i invest is it too high

570

is it too low what's it going to i used to look at them

571

and say look you can do what you want with your

572

money i'm actually investing something much more valuable than money at moderna

573

and that's my time on earth uh

574

so you be the judge of your money i think sweat equity

575

and capital equity are different

576

and these days i'm curious to immerse myself in this side of the business of biotech

577

if i may uh to understand what that return on investment looks like

578

and how do i best align it with the things

579

that i still inherently care about

580

which is translating science into medicine yeah yeah in the in

581

that vein i mean one of the first questions that investors ask,

582

one of the first questions that regulatory agencies ask when they're looking at investigational therapeutics is about unmet medical needs.

583

What does it address?

584

Lots of research in biotech builders thus go about their business searching for solutions to unmet medical needs.

585

Why not?

586

It potentially wins the favor of markets and agencies.

587

But you, on the other hand, And to have shared a somewhat, you know, at face value,

588

perhaps contrarian opinion that unmet medical need is not really what drives innovation in this industry.

589

So I guess I'd ask you for some explanation of that philosophy.

590

Explain yourself.

591

Yeah.

592

Well, you know, it struck me as I was starting out at GSK.

593

I remember at one point we said, okay, we're going to focus on lung cancer because it's an unmet need.

594

And being the flippant young guy that I was, I told the head of the division that actually if he wanted to have an impact on lung cancer, he didn't need to do much work.

595

GSK already had the best drug in their portfolio at the time.

596

And he goes, yeah, what is it?

597

He said, it's Nicorette.

598

unmet need hasn't changed.

599

And so we've had, you know, we've had cancer for eons.

600

And so it's not unmet need per se, that's driven all the new medicines we have.

601

So it's actually new understandings in science and technology that then that are driven primarily by curiosity.

602

You know, when Caitlin Carrico, whom I have a ton of respect for, started fiddling around with the structure of RNA to understand why, in some cases, was it killing cells

603

and what could she do to the chemistry to stop it from killing cells and get progene expressed.

604

She came upon a really interesting discovery, but nobody knew what to do with it.

605

In fact, the IP lay fallow for years.

606

They kind of licensed it to somebody else.

607

And it wasn't until people who actually said, huh, there's something that maybe we can get translated.

608

And even then, the first folks who picked that up, their idea of what to do with it was just following their curiosity.

609

Oh, can I reprogram the stem cell to go be something else?

610

Which is super interesting scientifically, but we still don't know how to make a medicine out of it.

611

And so for me, that bit of translation in the middle, pure innovation is opens up the potential.

612

That's the curiosity driven.

613

That's basic science.

614

That's basic technology.

615

When Bob Langer discovered that he could make lipid nanoparticles,

616

and Bob is a legendary MIT professor who's the father of the modern lipid nanoparticle and frankly, one of the fathers of the current ecosystem,

617

as we know it, of Boston Biotech.

618

And that's because of his deep understanding that when he discovered he could do something, and that something was everybody else thought he couldn't do it and shouldn't be possible,

619

that opened up a wonderful world of intellectual property.

620

And his understanding of the value of intellectual property

621

and the ability then to showcase what you could do with it to attract investment, that's what started the ball rolling.

622

And frankly, Moderna is sort of the culmination of the curiosity of people like Bob Langer,

623

like Caitlin Carrico, but actually putting it together in something that now is useful.

624

In fact, even in the early days of Moderna, we were exploring a whole bunch of different things and trying to make different types of therapies with it.

625

Moderna still is exploring the next frontier, whether it's cystic fibrosis or rare disease.

626

Now we know vaccines work and what happens is unmet need becomes the prism by

627

which you focus the light it's not the source of the light the source of the energy is actually

628

that scientific and technical innovation

629

and that's brilliant people who just are just super curious to go to go do something

630

or investigate something but the ability to then focus

631

that potential show through the prism of unmet need is what gets us medicine.

632

I think that's a really interesting distinction, especially given where we are right now,

633

I think with mRNA and you're positioning yourself right at the at the head of a brand new mRNA company, right? So,

634

you know, where there's still so much unknown unknowns right around the science of mRNA

635

and how it works and the delivery of it

636

and how it's going to perform in different cell types

637

and how we get it to express longer such there are

638

so many different scientific questions um

639

and we also you know tend to i think celebrate mra

640

at face value for the ability to manufacture more efficiently right

641

you've talked about this in comparison to other cell -based medicines right

642

so you know i'd be curious to get your sense on

643

the trajectory of innovation in this space what you really think is

644

are some of the the pieces here that are really driving further innovation in

645

that space right And that we are starting to funnel into unmet need to some extent to make these into therapies.

646

But what are those, you know, what's stoking the innovation in the mRNA space today that has you the most excited?

647

And what's at the root of that?

648

So I think the two current frontiers for mRNA medicines have to do still with the original questions in a way,

649

except we've moved the ball down the field.

650

The first is what cell can you get the mRNA into to mediate the protein translation

651

that would lead to a therapeutic benefit?

652

Vaccines were the low hanging fruit

653

because all you need is a needle in the arm and it goes to the local lymph nodes.

654

And all you need is a smidgen of protein produced and you mimic a viral infection and off you go.

655

The next place where you can put it is likely intravenous.

656

And I think that's also been proven.

657

And we've demonstrated, we at Moderna back in the day, shown that we can inject mRNA encoding just for an antibody intravenously

658

and it goes to the liver and it will make you antibody and you get therapeutic doses of antibody.

659

So can you get it to the lungs?

660

Can you get it to the bone marrow?

661

Can you get lupin nanoparticles into immune cells?

662

Can you get that into the brain?

663

I think that's some of the those are some of the frontier areas where people are trying to push the boundaries.

664

The next the other dimension is, well, what actually can you encode in the mRNA?

665

And initially, the place you start is the stuff that's best understood because you want to minimize risk.

666

And nothing is better understood than an antigen for a virus.

667

And, you know, it's no mistake

668

that all the COVID vaccines all use the exact same spike protein that everybody now knows what a spike protein is.

669

OK, that was easy.

670

But you could actually make proteins that are much more complicated.

671

You can make proteins that require several several subunits to come together

672

and you can make proteins that have not been seen in nature.

673

You can invent new proteins that have novel functions or improve on functions in very creative ways.

674

I am curious about that frontier personally, that's where Exilio comes in,

675

because for me, Exilio, this gene therapy company that I've now taken on,

676

is actually at the forefront.

677

It can combine innovation that comes from two different sources.

678

One of them is mRNA and a lipid nanoparticle as a drug format.

679

We can give it, it can go to cells where we understand can already go to, whether it's the liver or immune cells and it can translate protein

680

and you can actually give it repeatedly you can give it once twice three times in fact you know moderna

681

and their lead indications are have gone now for for about

682

a year in their first two diseases giving it every two to three weeks no problem

683

but the second thing is gene therapy can i actually integrate

684

a novel piece of genetic material in a safe way into the human genome to produce a therapeutic protein.

685

And then I don't have to keep treating that patient.

686

Well, that's as close to a cure as I know.

687

And so what this company

688

that I'm now running is trying to do is basically take

689

a page of evolution as a starting point of some elements that can actually do this in nature, but use modern tools of protein engineering to improve upon their utility

690

so that we can actually use mRNA

691

and a lipid nanoparticle as a way to bring gene therapy to the forefront

692

and do it not just by doing one or two small, you know, alterations of a genome,

693

but actually to insert an entire piece of missing genetic material and cure a kid with a genetic disease, for example.

694

And this, my friend, is where the cliffhanger comes in

695

because we do have a hard stop and

696

because my next series of questions we certainly cannot tackle in four minutes we cannot those questions those questions being

697

if curiosity is to be rewarded it it must be funded

698

who is funding curiosity who's willing to fund how do you

699

willing to fund these innovation come on in this market who's going to fun we're going to go down

700

that path we're going to get to know exilio uh in in detail

701

but we're not going to do it right now folks we're

702

going to do it in part two of this conversation

703

that i am um hereby committing dr tall zacks sorry you're

704

gonna have to come back to tell some more tall tales with pleasure colleagues

705

and we will have popcorn for that one we will have popcorn for that one.

706

I will bring the popcorn.

707

But for now, we are going to let you off the hook to meet your next commitment.

708

And I will be in touch with your people to get part two scheduled very, very quickly because I might get to run right on the heels of this one.

709

This has been a fascinating conversation and I appreciate your time.

710

Stay tuned.

711

I look forward to it.

712

Thank you so much.

713

Thank you.

714

Thank you.

715

So that's part one of Exilio Therapeutics, CEO and chair of the Board of directors, Dr. Tal Zaks.

716

I'm Matt Piller.

717

And I'm Anna Rose Welch.

718

You just listened to The Business of Biotech.

719

We're produced by Life Science Connect in support of a deep community of learning, solving, and sourcing solutions for biotech and life sciences leaders.

720

And if you haven't seen it yet, be sure to visit our video cast page under the listen and watch tab at bioprocessonline .com.

721

There you'll find this and hundreds of other videos of our interviews with biotech builders.

722

While you're there, subscribe to the Business of Biotech newsletter at bioprocessonline .com backslash B -O -B.

723

In the meantime, we'll see you next week, hopefully, for part two of Storytime with Tal.

724

And thanks for listening.

Скачать приложение

Всё для свободной речи

ИИ-оценка произношенияОценка каждой фразы

Практика IPAОсвойте каждый звук

СловарьСоберите свой словарный запас

Игра со словамиУчитесь играя

Сканировать QR

Download on theApp Store Get it onGoogle Play

FOR YOU

Лексика и советы по произношению к этому уроку

Этот урок разговорной практики построен на видео «Biotech Story Time With Tal Zaks, M.D». В этом видео 724 предложений и 9464 слов для шедоуинга. Речь длится 55:08. Говорящий говорит в естественном темпе, около 172 слов в минуту, близком к повседневной речи. 82% слов входят в 3000 самых частых слов английского языка; остальные стоит разобрать перед занятием.

Ключевая лексика этого видео

15 слов из видео, которые стоит выучить, с произношением и значением:

Слово	Произношение	Значение
vaccine существительное	/vækˈsin/	вакци́на, приви́вка
innovation существительное	/ˌɪn.əˈveɪ.ʃən/	нова́торство, иннова́ция
ecosystem существительное	/ˈikoʊˌsɪstəm/	экосисте́ма
popcorn существительное	/ˈpɑp.kɔɹn/	попко́рн
curious прилагательное	/ˈkjʊɹ.i.əs/	любопы́тный, любозна́тельный
protocol существительное	/ˈpɹoʊtəˌkɑl/	протоко́л
translate глагол	/tɹænzˈleɪt/	переводи́ть, перевести́
physician существительное	/fəˈzɪʃən/	врач, врачи́ха
innovative прилагательное	/ˈɪn.əˌveɪtɪv/	инновацио́нный
curiosity существительное	/ˌkjʊɹ.iˈɑ.sə.ti/	любопы́тство, любозна́тельность
builder существительное	/ˈbɪl.dəɹ/	строи́тель, строи́тельница
equity существительное	/ˈɛk.wɪ.ti/	справедли́вость, беспристра́стность
intellectual прилагательное	/ˌɪntəˈlɛkt͡ʃʊəl/	интеллектуа́льный, у́мственный
dose существительное	/ˈdəʊ̯s/	до́за
fortunate прилагательное	/ˈfɔɹ.t͡ʃə.nɪt/	благоприя́тный

Фразовые глаголы, которые вы услышите

Слово	Произношение	Значение
figure out глагол		разбира́ться, разобра́ться
come out глагол	/ˌkʌm ˈaʊt/	выходи́ть, вы́йти
go back глагол		возвраща́ться, возврати́ться
go down глагол		спуска́ться, спусти́ться
look forward to глагол		ждать с нетерпе́нием, не мочь дожда́ться
move forward глагол		продвига́ть, продви́нуть
pick up глагол		подбира́ть, подобра́ть
come back глагол		возвраща́ться, возврати́ться

Фразы, которые стоит повторять

Короткие законченные фразы из видео, которые пригодятся в повседневном разговоре:

Can you make a medicine?
Zax, what are you worried about?
Can you get it to the bone marrow?
Can you get lupin nanoparticles into immune cells?
Can you get that into the brain?

Грамматика в этом видео

Конструкции, которые говорящий использует чаще всего, с точными словами из видео:

Конструкция	В видео
Present Perfect Continuous have/has been + -ing — действие началось раньше и продолжается	have been working · he's been dreaming
«Used to» used to + глагол — прошлая привычка или состояние, которых больше нет	used to call · used to look
Present Perfect have/has + причастие прошедшего времени — прошлое действие, важное сейчас	it's been · has built · has become
Пассивный залог be + причастие прошедшего времени — важно, что происходит, а не кто это делает	being wrapped · were actually marked · is driven

Произношение, на которое стоит обратить внимание

Говорящий использует 144 сокращённых и редуцированных форм, например I'm, don't, we're. Произносите их коротко, так, как слышите.

Звуки «th»: therapeutic /ˌθɛɹ.əˈpjuː.tɪk/, theater /ˈθi(ə)tɚ/, ethics /ˈɛθ.ɪks/, theorist /ˈθiːəɹəst/, breadth /bɹɛdθ/
Звуки «sh» и «zh»: innovation /ˌɪn.əˈveɪ.ʃən/, physician /fəˈzɪʃən/, fellowship /ˈfɛl.ə.ʃɪp/, explanation /ˌɛkspləˈneɪʃən/, translation /tɹænzˈleɪʃən/
Длинные слова — следите за ударением: innovation /ˌɪn.əˈveɪ.ʃən/, ecosystem /ˈikoʊˌsɪstəm/, innovative /ˈɪn.əˌveɪtɪv/, curiosity /ˌkjʊɹ.iˈɑ.sə.ti/, intellectual /ˌɪntəˈlɛkt͡ʃʊəl/

Звуки, трудные для русскоязычных:

/w/ — губы округлены, это не /v/: equity /ˈɛk.wɪ.ti/, reward /ɹɪˈwɔɹd/, sweat /swɛt/, subsequent /ˈsʌbsɪkwənt/, welch /wɛlt͡ʃ/
/h/ — лёгкий выдох, а не русское «х»: household /ˈhaʊshoʊld/, horrible /ˈhɔɹ.ɪ.bəl/, hire /ˈhaɪɹ/, hook /hʊk/, cliffhanger /ˌklɪfˈhæŋ.ə(ɹ)/
Звонкие согласные в конце слова — не оглушайте их: innovative /ˈɪn.əˌveɪtɪv/, reward /ɹɪˈwɔɹd/, household /ˈhaʊshoʊld/, slide /ˈslaɪ̯d/, colleague /ˈkɒliːɡ/

Как заниматься с этим видео

Прослушайте всё видео один раз молча и выпишите незнакомые слова.
Начните со скорости 0,75×, повторяйте предложение за предложением и вернитесь к обычной скорости, когда станет легко.
Запишите себя и сравните с оригиналом, обращая внимание на такие слова, как vaccine, innovation, ecosystem.

Что такое техника Shadowing?

Shadowing — это научно обоснованная техника изучения языка, изначально разработанная для подготовки профессиональных переводчиков и популяризированная полиглотом доктором Александром Аргуэльесом. Метод прост, но эффективен: вы слушаете аудио на английском от носителей языка и немедленно повторяете вслух — как тень, следующая за говорящим с задержкой в 1–2 секунды. В отличие от пассивного прослушивания или грамматических упражнений, Shadowing заставляет мозг и мышцы рта одновременно обрабатывать и воспроизводить реальные речевые паттерны. Исследования показывают, что это значительно улучшает точность произношения, интонацию, ритм, связную речь, понимание на слух и беглость речи — что делает его одним из самых эффективных методов для подготовки к IELTS Speaking и реального общения на английском.

Техника шедоуинга: читать полное пошаговое руководство →

Практика Shadowing: Biotech Story Time With Tal Zaks, M.D. (Part 1) - Изучайте разговорный английский по видео

Выберите режим практики

Скачать приложение

Рекомендуемое видео

Inside a Biotech Company: Roles, Teams & Where You Could Fit In | EP 14

The unstoppable green revolution: Adam Tooze on the "most dramatic story in the history of energy”

Leaders of Neurosurgery: Jacques Morcos, MD, FAANS, FACS interviewed by Gregory Zipfel, MD, FAANS

Mark Zuckerberg: “Alex, are you sure this is going to work?”

View From The Top with Roelof Botha, Managing Partner of Sequoia Capital

The Longevity Toolkit: Peter Attia’s 5 Tactics to Improve Longevity

Trust the Process: How to Design Teams That Actually Work

Sec Growth DataScience staff meeting Sep 14 2022

Daniel Ek: Life After Spotify, Broken Healthcare Incentives, Catching Disease Early & AI's Potential

Day in the Life as a Doctor

The Only SaaS Moats Left in 2026

What Actually Works for Your Skin? A Stanford-Trained Plastic Surgeon Explains

Лексика и советы по произношению к этому уроку

Ключевая лексика этого видео

Фразовые глаголы, которые вы услышите

Фразы, которые стоит повторять

Грамматика в этом видео

Произношение, на которое стоит обратить внимание

Как заниматься с этим видео

Что такое техника Shadowing?